pharma · Ulcerative Colitis · Multiple Myeloma
AbbVie Deutschland GmbH
AbbVie Deutschland GmbH & Co. KG
APONTIS PHARMA Deutschland is a pharma organization headquartered in Wiesbaden, DE. Primary therapeutic focus areas include Ulcerative Colitis, Multiple Myeloma, Neovascular age-related macular degeneration, Psoriatic Ar
Company details
- Status
- Public
- HQ
- Wiesbaden, DE
- Founded
- 2018
- Employees
- 101
- Programs
- 102
- Drugs
- 119
- Patents
- 23
M16-573
Phase 1 · other · Patients with relapsed or refractory solid tumors, including: Small cell lung cancer (SCLC); Non-small cell cancer (NSCLC); Breast cancer
M16-573 for Patients with relapsed or refractory solid tumors, including: Small cell lung cancer (SCLC); Non-small cell cancer (NSCLC); Breast cancer is a Phase 1 program (other) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).
Internal code M16-573
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- AbbVie Deutschland GmbH & Co. KG
- Phase
- Phase 1
- Modality
- other
- Indication
- Patients with relapsed or refractory solid tumors, including: Small cell lung cancer (SCLC); Non-small cell cancer (NSCLC); Breast cancer
- Status
- active
- Trials
- 1